Aker BioMarine ASA – Completion of Feed Ingredients transaction

03 Sep 2024 15:33 CEST

Fornebu, September 3, 2024 – On July 3, 2024, Aker BioMarine ASA announced that
it had entered into an agreement with American Industrial Partners and Aker
Capital AS for the sale of its ownership stake in the Feed Ingredients business.
On August 5, 2024, the company informed that the transaction had received
clearance from all relevant competition authorities, and today, the share sale
has been completed.

Based on an enterprise value of USD 590 million, the total transaction proceeds
adjusted for normalized working capital and excess product inventory at closing
will amount to USD 630 million, of which USD 610 million is settled today and
USD 20 million will be settled within 90 days. After settling the company’s
outstanding debt and broker fees, the net cash proceeds to Aker BioMarine will
be USD 227 million.

Aker BioMarine intends to distribute an extraordinary dividend of approximately
NOK 45 per share following completion of the transaction, subject to final
decision by the Board of Directors. In today’s extraordinary general meeting,
the company’s Board of Directors was granted authorization to distribute
dividends.

Following the transaction, Aker BioMarine will be a focused human health and
nutrition company consisting of three business units: (1) Human Health
Ingredients, (2) Consumer Health Ingredients, and (3) Emerging Businesses.

"The sale represents an important milestone in crystallizing value and allows
Aker BioMarine to focus on the human health and nutrition business. The company
holds an attractive position in the growing dietary nutrition market,
particularly within the large Omega-3 segment. We will continue to grow by
increasing market share and expanding our product categories through innovation.
Our business model will be capital-light, with the potential for high cash
conversion," says Matts Johansen, CEO of Aker BioMarine.

Arctic, Carnegie, and Rabobank acted as financial advisors to Aker BioMarine in
connection with the transaction, with Schjødt serving as legal advisor.

For further information, please contact:

Christopher Robin Vinter, VP IR & Corporate Finance
Mobile: +47 911 60 820
Email: Christopher.vinter@akerbiomarine.com

For media:

Tormod Sandstø, Director of Communications
Mobile: +47 909 43 215
Email: tormod.sandsto@akerbiomarine.com


About Aker BioMarine
Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting
company developing krill-derived products for consumer health and wellness as
well as animal nutrition. The company has a strong position in its industry and
is the world's leading supplier of krill, the natural, powerful and health
promoting source of nutrients from the pristine waters of Antarctica. Aker
BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available
at www.akerbiomarine.com.

This information is subject to the disclosure requirements pursuant to Section
5-12 the Norwegian Securities Trading Act and contains information deemed to
constitute inside information pursuant to the European Market Abuse Regulation.

This announcement was published by Christopher Robin Vinter, VP IR & Corporate
Finance of Aker BioMarine ASA on 3 September 2024.

More information:
Access the news on Oslo Bors NewsWeb site